Cidara Therapeutics (CDTX) 10-K2020 FY Annual report

Filed: 25 Feb 21, 4:36pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accuracy, Aid, anesthesiologist, assumption, backstopped, Biden, biobanking, bona, Britain, carryback, certified, chain, Chinese, compliant, confiscation, constitutionality, contact, convene, cooperation, corroborative, CRO, cyber, Cyberspace, deadly, dictated, element, encompassing, entertain, epidemiology, EPS, facially, fide, flux, front, Graft, Great, HGR, IIP, immaterial, immunodeficiency, immunosuppression, incompatible, indefinitely, invoice, left, loaded, lowest, LP, marker, marketplace, Ministry, monkey, moving, NaN, nationwide, necessity, network, NOL, Northern, Notably, nurse, offshore, offsite, ofthe, onshore, ouraudit, paused, peptide, perception, PIP, precautionary, presidential, quarantine, rat, recourse, reexamining, regular, remote, remotely, Republic, retroactively, retrospective, risky, Science, sequester, shutdown, Singapore, SmPC, sought, speculative, stem, Stonepine, syncytial, Taiwan, talented, tariff, temporarily, tension, Thailand, thematter, tie, titled, top, transmit, umbrella, uncollectible, undergone, unemployment, unlimited, unnecessary, urgent, usability, venue, vigilant, vigorously, virtually, Watch, weaddressed, workforce, yearly

Removed: Accelerator, bacteria, BARDA, billed, Biomedical, Boston, BPCA, budgeted, Combating, concept, cure, curve, decided, discontinued, endpoint, feedback, foundation, fringe, gave, gel, golden, half, inadequately, IPO, irrevocably, Jumpstart, leverage, managed, NIAID, nonbinding, nondeductible, ointment, owed, parachute, prepaid, proof, proposal, Rebate, School, sourced, subaward, subawardee, topical, Trust, UNAUDITED, University, VVC, Wellcome

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CDTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Cidara Therapeutics, Inc. (the “Company”) for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof and to which this certification is attached as an exhibit (the “Report”), I, Jeffrey Stein, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: February 25, 2021	By:	/s/ Jeffrey Stein, Ph.D.
		Jeffrey Stein, Ph.D. President and Chief Executive Officer
		(Principal Executive Officer)

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cidara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.